+1-518-621-2074 | US-Canada Toll Free Contact Us

Enhancement of Automated Testing Levels to Encourage Growth of In Vitro Diagnostics Market in China

about us

Published on : Aug 30, 2016

ALBANY, New York, August 30, 2016: ResearchMoz.us has announced the inclusion of a new market research study to its comprehensive collection of research reports. The 90-page research study, “China In Vitro Diagnostics (IVD) - Opportunity Assessment, Competitive Landscape, and Market Forecasts to 2021,” offers a thorough analysis, emphasizing on the potential growth opportunities and trends in the market. In addition, the primary growth drivers, barriers, product segmentation, and the competitive landscape of the China in vitro diagnostics market have been included in the research report.

Furthermore, the research study provides the historical data and forecast figures of the in vitro diagnostics market in China, along with the projected growth rates. The strategic inputs given by industry specialists have been included in the research study in order to give a clear picture of the overall market. The analytical tools used in the study benefits in determining the opportunities that are estimated to encourage the growth of the market in the near future.

The development of automated testing levels and growing investment in healthcare infrastructure are some of the primary factors estimated to augment the growth of the in vitro diagnostics market in China in the next few years. In addition, the favorable healthcare reforms and rising number of independent testing laboratories and private hospitals are expected to bolster the China IVD market throughout the forecast period. The rising incidence of cardio-cerebrovascular illnesses, hypertension, diabetes, cancer, and arthritis and growing health awareness among the population are further projected to drive the China in vitro diagnostics market in the coming years.

Click here to get more info with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=785417

On the flip side, the low reimbursement rate of the essential healthcare insurance plans for clinical tests is anticipated to curtail the growth of the in vitro diagnostics market in China. Moreover, the existing reimbursement policy rates vary in different parts of China, which creates difficulties while promoting in vitro diagnostics products, thus restraining the growth of the market. In addition, the lack of quality products by regional companies is projected to hamper the growth of the overall market in the next few years.

The China market for in vitro diagnostics has been categorized on the basis of type into immunoassay, microbiology, POCT, molecular testing, clinical chemistry, cytology, and others. Among these, the immunoassay segment is estimated to grow at a fast pace in the next few years, registering a robust growth in the overall market. On the other hand, the molecular testing and clinical chemistry segments are expected to witness substantial growth in the coming few years.

The leading product companies in the in vitro diagnostics market in China include Mingyuan Medicare, Da An Gene Co. Ltd., Shanghai Fosun Pharmaceutical Group, Shanghai Kehua Bio–Engineering Co. Ltd., and Mindray Medical International Limited. Some of the private diagnostic services companies and clinical labs leading the China IVD market are Zhejiang Dian Diagnostics Technology Co., Ltd., Guangzhou Kingmed Diagnostics Center Co. Ltd., Kindstar Global, OriGene Technologies, ADICON Clinical Laboratories, and BGI – Shenzhen.

To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on [email protected]